Year: 2007
Type: article
Abstract: The Recombinant DNA Advisory Committee (RAC) meeting on 17 September 2007 reviewed the serious adverse event that occurred in the adeno-associated virus (AAV) trial for rheumatoid arthritis patients. A participant in the trial died some 3 weeks after she received a second intra-articular injection of an AAV2 vector encoding a fusion of the IgG1 Fc and tumor necrosis factor-α (TNF-α) receptor. This fusion is identical to the construct utilized to manufacture the TNF-α antagonist drug etanercept (Enbrel).
Source: Molecular Therapy
Author: David A Williams
Language: English
Subfield: Genetics
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $4,500
OpenAlex ID: W2046467474